Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Queensland Farmer Preparing to Enter MND Drug Trial

Queensland Farmer Preparing to Enter MND Drug Trial

November 21, 2026 Health Desk Health

A 49-year-old Queensland cattle farmer is preparing to enter a phase 2 clinical trial for motor neurone disease (MND), aiming to extend her time with family after receiving a diagnosis in August.

    Key Clinical Takeaways:

  • The NUN-004 trial, involving 75 participants, targets the EphA4 receptor to protect nerve cells and potentially repair damaged neural connections.
  • Initial findings from a six-month phase 1 study indicated that some patients experienced stabilized conditions and improvements in strength and balance.
  • The therapy is the culmination of 25 years of research conducted at the University of Queensland and is now being developed by the biotechnology firm NuNerve.

Clinical Progression of MND

Julianne McLean, who has managed a cattle and crop farm in Kilkivan for over two decades, first noticed symptoms of the disease in her left leg. The condition rapidly progressed to include foot drop, spinal issues, and vocal degeneration.

Antony Winkel, director of neurology at Sunshine Coast University Hospital (SCUH), describes the condition as a progressive neurological disorder that causes the deterioration of motor neurons, preventing the brain from signaling muscles effectively, ABC News reported.

The prognosis for patients remains difficult. “The life expectancy is only two or three years after a diagnosis and, because we know the diagnosis can be quite delayed, the average survival in MND is about three to five years,” Dr. Winkel told ABC News.

“It’s one of those really nasty diseases where it doesn’t matter what you do, you know the next day is going to be harder in some way,” Dr. Winkel told ABC News.

Therapeutic Mechanism and Trial Scope

The upcoming phase 2 trial, which will recruit 75 participants, is designed to evaluate the efficacy of NUN-004. This protein-based therapy works by inhibiting the EphA4 receptor, which researchers have identified as a contributor to motor neurone degeneration and impaired nerve recovery.

According to Perry Bartlett, chief scientific officer of NuNerve and founder of the University of Queensland’s Queensland Brain Institute, the study will involve continuous administration of the molecule over 12 months.

Farmer hopes mnd trial could give her more time with family
Photo: khanlist.com

“We hope it's fundamentally a game changer in the field,” Perry Bartlett, chief scientific officer of NuNerve and founder of the University of Queensland's Queensland Brain Institute, said.

Trial Parameter Clinical Detail
Phase 2 Recruitment 75 participants
Research Duration 25 years
Therapy Target EphA4 receptor

The trial will be conducted across multiple sites, including SCUH, Brisbane, Perth, Sydney, and Newcastle. While initial observations showed promising signs of stabilization in some of the eight participants from the first phase, Stacey Thorpe, chief executive of MND Queensland, emphasized that further rigorous testing remains necessary to confirm both safety and clinical effectiveness, ABC News reported.

Impact on Patient Care

For individuals facing a terminal diagnosis with limited standard-of-care options, clinical trials represent a major, though uncertain, path toward hope. Ms. McLean, who is bracing for her physical decline, views the trial as an opportunity to secure more time with her husband and teenage daughters. “Anytime you’re given a terminal diagnosis and that there’s officially no cure, the first thing that you lose is hope,” she told ABC News.

“The impact the disease has sticks with families for the rest of their days. It's horrendous to watch,” Dr. Winkel told ABC News.

The University of Queensland, established in 1909, is one of the six sandstone universities, a designation for the oldest institutions in each Australian state. Based primarily in Brisbane, the university has long been a center for scientific advancement, counting among its achievements the invention of the HPV vaccine that prevents cervical cancer and the development of high-performance superconducting MRI magnets for portable limb scanning.

The research team intends to continue the development of NUN-004 through their commercial entity, NuNerve, with the phase 2 trial scheduled to commence next year. Researchers hope the intervention will move beyond merely slowing disease progression to actively restoring lost functions in affected patients.

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related reading

  • Study Finds Unique Epigenetic Brain Signatures in PTSD
  • AI Clones ORF Anchor Sophie Ströbitzer Voice for Viral Fake News on TikTok

Related

Clinical Trial

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service